Targeted delivery of intranasally administered nanoparticles-mediated neuroprotective peptide NR2B9c to brain and neuron for treatment of ischemic stroke.

The lack of effective therapies mandates the development of new treatment strategies for ischemic stroke. The NR2B9c peptide can prevent N-Methyl-D-aspartate receptor (NMDAR)-mediated neurotoxicity induced by ischemia without affecting essential NMDAR activity and brings hope for stroke therapy. However, it is very difficult for NR2B9c to cross by itself the blood-brain barrier (BBB) and the neuron membrane. To provide a suitable delivery for unleashing the therapeutic potential of NR2B9c, in consideration of a high affinity of wheat germ agglutinin (WGA) for WGA receptors abundantly present on olfactory epithelium and neuronal surface, we developed WGA-modified nanoparticles carrying NR2B9c (NR2B9c-WGA-NPs). Following intranasal administration, NR2B9c-WGA-NPs are able to bypass the BBB and effectively transport NR2B9c into the brain and neuron, and therefore can protect neurons against excitotoxicity, reduce ischemic brain injury in rats and ameliorate their neurological function deficits. The intranasal administration of NR2B9c-WGA-NPs may serve as a practical stroke therapy.

• Publication year

  2019

• Venue

  Nanomedicine : nanotechnology, biology, and medicine

• Publication date

  2019-06-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1016/j.nano.2018.10.013PMID 30428334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Restoring brain function after stroke — bridging the gap between animals and humans

  2017cited by this paper
• Neuroprotective efficacy of poly-arginine R18 and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat.

  2017cited by this paper
• Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association

  2017cited by this paper
• Tau-mediated iron export prevents ferroptotic damage after ischemic stroke

  2017cited by this paper
• Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.

  2016cited by this paper
• Neuropsychiatric sequelae of stroke

  2016cited by this paper
• Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

  2016cited by this paper
• Wheat germ agglutinin modification of lipid–polymer hybrid nanoparticles: enhanced cellular uptake and bioadhesion

  2016cited by this paper
• Metabotropic NMDA receptor signaling couples Src family kinases to pannexin-1 during excitotoxicity

  2016cited by this paper
• Brain targeting by intranasal drug delivery (INDD): a combined effect of trans-neural and para-neuronal pathway

  2016cited by this paper
• Egg drop syndrome virus enters duck embryonic fibroblast cells via clathrin-mediated endocytosis.

  2015cited by this paper
• Cell-penetrating peptides: strategies for anticancer treatment.

  2015cited by this paper
• Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats

  2015cited by this paper
• Therapeutic Targets for Cerebral Ischemia Based on the Signaling Pathways of the GluN2B C Terminus.

  2015cited by this paper
• Insights into direct nose to brain delivery: current status and future perspective

  2014cited by this paper
• Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis.

  2014cited by this paper
• Quantitative analysis of drug delivery to the brain via nasal route.

  2014cited by this paper
• Direct cellular delivery of human proteasomes to delay tau aggregation

  2014cited by this paper
• Gram-scale synthesis of single-crystalline graphene quantum dots with superior optical properties

  2014cited by this paper
• Stability of an anti-stroke peptide: driving forces and kinetics in chemical degradation.

  2014cited by this paper
• NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease

  2013cited by this paper
• Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting

  2013cited by this paper
• Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin.

  2013cited by this paper
• Cellular Uptake Mechanisms of Novel Anionic siRNA Lipoplexes

  2013cited by this paper
• Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation.

  2013cited by this paper
• PLGA-based nanoparticles: an overview of biomedical applications.

  2012cited by this paper
• A Translational Paradigm for the Preclinical Evaluation of the Stroke Neuroprotectant Tat-NR2B9c in Gyrencephalic Nonhuman Primates

  2012cited by this paper
• Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain

  2012cited by this paper
• In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles.

  2012cited by this paper
• Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration

  2011cited by this paper
• Nose-to-Brain Transport Pathways of Wheat Germ Agglutinin Conjugated PEG-PLA Nanoparticles

  2011cited by this paper
• Effect of wheat germ agglutinin density on cellular uptake and toxicity of wheat germ agglutinin conjugated PEG-PLA nanoparticles in Calu-3 cells.

  2011cited by this paper
• CaMKII in cerebral ischemia

  2011cited by this paper
• In vitro Nasal Cell Culture Systems for Drug Transport Studies

  2010cited by this paper
• Gene transfer in the nervous system and implications for transsynaptic neuronal tracing

  2010cited by this paper
• Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95

  2010cited by this paper
• Reducing prehospital delay in acute stroke

  2009cited by this paper
• Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier

  2009cited by this paper
• Role of NMDA receptor–dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries

  2009cited by this paper
• Effectiveness of PSD95 Inhibitors in Permanent and Transient Focal Ischemia in the Rat

  2008cited by this paper
• Wheat germ agglutinin-modified trifunctional nanospheres for cell recognition.

  2007cited by this paper
• VEGF overexpression enhances striatal neurogenesis in brain of adult rat after a transient middle cerebral artery occlusion

  2007cited by this paper
• Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.

  2007cited by this paper
• Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.

  2006cited by this paper
• Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles.

  2006cited by this paper
• Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions

  2002cited by this paper
• Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein.

  1999cited by this paper
• Nasal mucociliary clearance as a factor in nasal drug delivery.

  1998cited by this paper
• Lectins bind differentially to cilia and microvilli of major and minor cell populations in olfactory and nasal respiratory epithelia

  1992cited by this paper
• Synaptic organization of the mammalian olfactory bulb.

  1972cited by this paper

• Enhanced Nasal-to-Brain Drug Delivery by Multivalent Bioadhesive Nanoparticle Clusters for Cerebral Ischemic Reperfusion Injury Protection.

  2025cites this paper
• Intranasal delivery of metformin using metal–organic framework (MOF)-74-Mg nanocarriers

  2025cites this paper
• Challenges and strategies for nose-to-brain delivery in treating neurological disorders

  2025cites this paper
• Biomaterials for CNS disorders: a review of development from traditional methods to AI-assisted optimization

  2025cites this paper
• Intranasal Therapeutics for Neurodegenerative Disorders: Overcoming the Blood-Brain Barrier with Smart Formulations and Devices.

  2025cites this paper
• The Nasal–Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases

  2025cites this paper
• Advancements in Protein-Based Therapeutic Delivery Approaches Targeting the Blood-Brain Barrier and Insights on Computational Strategies.

  2025cites this paper
• Celery seed derived reconstituted lipid nanoparticles as an innate neuron-targeted neuroprotective nanomedicine for ischemic stroke treatment

  2025cites this paper
• Intranasal Poly(Lactic-co-Glycolic Acid) Nanoparticles of Mefenamic Acid Improve Motor Expressions and Neurochemical Injury in Aluminium Chloride Originated Alzheimer’s Disease

  2025cites this paper
• Dodecyl creatine ester, a promising treatment to deliver creatine to neurons, achieves pharmacology efficacy in creatine transporter deficiency.

  2024cites this paper
• Micro/nanoparticle-enabled ultrasound therapy of brain diseases

  2024cites this paper
• An Update on Recent Drug Delivery Systems Targeting Brain Diseases via the Transnasal Pathway

  2024cites this paper
• Non-Invasive Techniques of Nose to Brain Delivery Using Nanoparticulate Carriers: Hopes and Hurdles

  2024cites this paper
• Demystifying Multipronged Approaches of Wheat Germ Agglutinin-Mediated Drug Delivery, Targeting, and Imaging: An Explicative Review

  2024cites this paper
• Nano revolutions in ischemic stroke: A critical analysis of current options and the potential of nanomedicine in diagnosis and therapeutics.

  2024cites this paper
• Advances in nanoparticle-based therapeutics for ischemic stroke: Enhancing drug delivery and efficacy.

  2024cites this paper
• Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides.

  2024cites this paper
• To see or not to see: In vivo nanocarrier detection methods in the brain and their challenges.

  2024cites this paper
• Nose-to-brain delivery of nanotherapeutics: Transport mechanisms and applications.

  2024cites this paper
• PLGA nanoparticles for nasal drug delivery

  2024cites this paper
• Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders

  2023cites this paper
• Current trends and future perspectives of stroke management through integrating health care team and nanodrug delivery strategy

  2023cites this paper
• The Development of Drug Delivery Systems for Efficient Intracranial Hemorrhage Therapy

  2023cites this paper
• Perspective insights into hydrogels and nanomaterials for ischemic stroke

  2023cites this paper
• Cell-Membrane-Coated Nanoparticles for Targeted Drug Delivery to the Brain for the Treatment of Neurological Diseases

  2023cites this paper
• Restoration of GABAB receptor expression in cerebral ischemia: a promising novel neuroprotective strategy

  2023cites this paper
• Application of Nanotechnology-Based Products in Stroke.

  2023cites this paper
• Nose-to-brain drug delivery for the treatment of CNS disease: New development and strategies.

  2023cites this paper
• Enhanced Immune Responses to Mucosa by Functionalized Chitosan-Based Composite Nanoparticles as a Vaccine Adjuvant for Intranasal Delivery.

  2022cites this paper
• Dodging blood brain barrier with “nano” warriors: Novel strategy against ischemic stroke

  2022cites this paper
• Nanoparticle mediated gene therapy: a trailblazer armament to fight CNS disorders.

  2022cites this paper
• Targeting the Interaction of GABAB Receptors With CHOP After an Ischemic Insult Restores Receptor Expression and Inhibits Progressive Neuronal Death

  2022cites this paper
• Progresses and Prospects of Neuroprotective Agents-Loaded Nanoparticles and Biomimetic Material in Ischemic Stroke

  2022cites this paper
• Targeting the interaction of GABAB receptors with CaMKII with an interfering peptide restores receptor expression after cerebral ischemia and inhibits progressive neuronal death in mouse brain cells and slices

  2022cites this paper
• Cyclovirobuxine D Brain-Targeted Liposomes Improve Cerebral Ischemia-Reperfusion Injury via Anti-Oxidant Stress and Activating Autophagy.

  2022cites this paper
• Recent Advances in Targeted Nanotherapies for Ischemic Stroke.

  2022cites this paper
• On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles

  2022cites this paper
• Advances in the research of nano delivery systems in ischemic stroke

  2022cites this paper
• Targeted Delivery of Intranasally Administered Cyclovirobuxine D Liposomes to Brain for Treatment Cerebral Ischemia-Reperfusion Injury via Anti-oxidative Stress and Activating Autophagy

  2022cites this paper
• PEI modified orange emissive carbon dots with excitation-independent fluorescence emission for cellular imaging and siRNA delivery

  2021cites this paper
• Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.

  2021cites this paper
• Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

  2021cites this paper
• Using nanotechnology to deliver biomolecules from nose to brain — peptides, proteins, monoclonal antibodies and RNA

  2021influential citation
• Targeted Delivery of Intranasally Administered Cyclovirobuxine D Liposomes to Brain for Treatment Cerebral Ischemia-Reperfusion Injury via Anti-oxidative Stress and Activating Autophagy

  2021cites this paper
• Nanotechnological advances in direct nose-to-brain drug delivery for neurodegenerative disorders and other neuroailments

  2021cites this paper
• Strategies for enhanced direct nose-to-brain drug delivery

  2021cites this paper
• Nose-to-brain delivery of biologics and stem cells

  2021cites this paper
• Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines

  2021cites this paper
• Nanoparticles-mediated emerging approaches for effective treatment of ischemic stroke.

  2021cites this paper
• Targeting Systems to the Brain Obtained by Merging Prodrugs, Nanoparticles, and Nasal Administration

  2021cites this paper
• Biomaterials to Neuroprotect the Stroke Brain: A Large Opportunity for Narrow Time Windows

  2020cites this paper
• Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease

  2020cites this paper
• Probing the drug delivery strategies in ischemic stroke therapy

  2020cites this paper
• Intranasal Delivery of Targeted Nanoparticles Loaded With miR-132 to Brain for the Treatment of Neurodegenerative Diseases

  2020cites this paper
• Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies

  2020cites this paper
• In silico Approach for Designing Potent Neuroprotective Hexapeptide.

  2019cites this paper
• Advanced Functional Materials and Cell‐Based Therapies for the Treatment of Ischemic Stroke and Postischemic Stroke Effects

  2019cites this paper
• DDDT_A_226473 3669..3682

  2019cites this paper
• A Novel Octapeptide Derived From G Protein-Coupled Receptor 124 Improves Cognitive Function Via Pro-Angiogenesis In A Rat Model Of Chronic Cerebral Hypoperfusion-Induced Vascular Dementia

  2019cites this paper
• Neuronanotechnology for brain regeneration.

  2019cites this paper